AUG7 Antibody

Monoclonal Antibody Nomenclature and Structure

Antibodies are typically named according to standardized conventions (e.g., AU-007 in or anti-α4β7 in ). These names often reflect their target (e.g., IL-2, PD-1) or structural features (e.g., IgG subclass).

• Example: AU-007 is a computationally designed monoclonal antibody (mAb) targeting IL-2’s CD25 binding epitope, redirecting immune responses toward T effector and NK cells while avoiding Treg activation .

Therapeutic Applications

• Cancer: Antibodies like avelumab (anti-PD-L1) and loncastuximab tesirine (anti-CD19 ADC) target tumor-specific markers .

• Infectious Diseases: Regdanvimab (anti-SARS-CoV-2) neutralizes viral particles, while obiltoxaximab prevents anthrax .

• Autoimmune Disorders: Dupilumab (anti-IL-4Rα) and reslizumab (anti-IL-5) modulate inflammatory pathways .

AU-007 (Phase 1/2 Study)

Anti-α4β7 in HIV/SIV Studies

• Reduced gut viral loads and myeloid cell turnover in SIV-infected macaques, suggesting potential for mucosal immune modulation .

Antibody Development Workflows

• Preclinical Testing: Includes epitope mapping, affinity measurements, and functional assays (e.g., ADCC, complement activation) .

• Clinical Trials: Phase 1/2 studies assess safety, pharmacokinetics, and preliminary efficacy (e.g., AU-007 trial ).

Data Gaps and Recommendations

• The term "AUG7 Antibody" does not appear in the provided sources. Potential causes include:

  1. Typographical error (e.g., AU-007 vs. AUG7).

  2. Obscure or developmental compound not yet published.

• For further investigation, consider:

  • Validating the antibody name with public databases (e.g., ClinicalTrials.gov, WHO INN).

  • Exploring structural or functional similarities to existing antibodies (e.g., anti-IL-2 mAbs like AU-007).